Tyra Biosciences stock tumbles 30% on phase 2 trial results
Tyra Biosciences (NASDAQ: TYRA) shares dropped 30% after reporting Phase 2 trial results for dabogratinib. The drug showed a 79% overall response rate and 64% complete response rate in combined patients. The trial enrolled 44 participants, with safety results indicating low rates of severe adverse events. Tyra plans to continue enrollment and engage with health authorities for Phase 3 study design.
How this was made
The 30-second read
Why it matters
The 30% price drop reflects immediate market skepticism despite high response rates; future pricing will hinge on safety and Phase 3 plans.
Market read
The trial results create short‑term volatility for TYRA and may affect peer biotech valuations.
What to watch
Potential for partnership or licensing deals if data are validated in larger cohorts.
Background
Tyra Biosciences is a Nasdaq‑listed biotech developing FGFR3 inhibitors for bladder cancer.
Ticker impact
TYRA stock dropped 30% after the company released Phase 2 SURF302 trial data showing a 79% overall response rate.
Further downside expected if additional data do not improve safety profile.
A 30% intraday move on fresh trial data suggests strong market reaction; investors will likely adjust positions today.
Market effects
Phase 2 data may influence sentiment toward other FGFR3‑targeted biotech firms.
Limited to US biotech sector; no broader regional effect.
Minimal global impact beyond niche oncology investors.
Counterpoint
If safety data hold, the efficacy could drive a rebound once Phase 3 design is clarified.
Key entities
- companyTyra Biosciences
Developer of dabogratinib, a FGFR3‑targeted therapy.
